Work

Could mRNA delivery of OAS3 and RNase L provide a novel broad-spectrum antiviral therapy?

Year: 2025

Type: article

Abstract: The development of novel antiviral drugs is urgently needed due to the high mortality caused by viral infections. Emerging viral strains and highly transmissible pathogens further increase this threat. Recently, the COVID-19 pandemic has resulted in millions of deaths worldwide, and it is highly probable that it will not be the last pandemic to emerge. Therefore, there is a pressing need for new therapeutic options that offer improved efficacy and safety. These options would enable physicians and patients to select the most appropriate treatment for each clinical situation. In this context, the present article aims to encourage discussion and research on the development of innovative antiviral therapeutics by proposing a hypothesis for a novel potential antiviral drug. Specifically, this manuscript explores the concept of using messenger RNA, encapsulated in lipid nanoparticles, to encode 2′,5′-oligoadenylate synthetase 3 and latent ribonuclease. The manuscript also discusses the potential advantages, limitations, and translational considerations of this approach in comparison with existing antiviral therapies.

Source: Medical Hypotheses

DOI: 10.1016/j.mehy.2025.111822

Author: Kevin Ricardo Espinosa Yépez

Institution: Universidad de Las Américas

Language: English

Topic: interferon and immune responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,820